Venous thromboembolism: A Call for risk assessment in all hospitalised patients

ISTH Steering Committee for World Thrombosis Day*

Thrombosis is a major contributor to the global burden of disease because it is the pathology underlying venous thromboembolism (VTE), ischaemic heart disease, and ischaemic stroke (1). Collectively, these disorders account for about 1 in 4 deaths worldwide (1). Prevention and treatment of thrombosis are critical for reducing global death and disability.

In 2014, the International Society on Thrombosis and Haemostasis (ISTH) declared October 13 as World Thrombosis Day to increase global awareness about thrombosis, including its risk factors and strategies for prevention, diagnosis, and treatment. VTE was selected as the initial focus of World Thrombosis Day because well-established public awareness campaigns were already focusing on heart disease and stroke through World Heart and World Stroke Days. More specifically, hospital-associated VTE was chosen as the focus for increased awareness and action.

This decision was supported by several pieces of evidence. First, there are compelling data from Europe and the United States documenting the burden of VTE, which includes deep-vein thrombosis (DVT) and pulmonary embolism (PE). Cohen et al. estimated that in 2004 there were more than 600,000 DVT events, 400,000 PE events, and 500,000 VTE-related deaths, across the European Union (2). In the United States, investigators from the Centers for Disease Control and Prevention estimated that there were more than 500,000 adult hospitalisations with a diagnosis of VTE each year from 2007 to 2009 (3). VTE is responsible for more deaths each year than breast cancer, HIV disease, and motor vehicle crashes combined (2).

Second, the available epidemiologic data indicate that approximately 60% of cases of VTE are associated with a recent hospital stay (4). The World Health Organisation (WHO) patient safety program found that hospital-associated VTE was a leading cause of death and disability associated with hospitalisation in low, middle, and high income countries and accounted for more deaths and greater disability than nosocomial pneumonia, catheter-related bloodstream infections, and adverse drug events (5).

Public awareness about VTE is low, and lags behind that of other common disorders (6). In a global survey, only 44% and 54% of respondents were aware of DVT and PE, respectively, and only 45% of respondents were aware that most cases of VTE were preventable (6). Even fewer identified hospitalisation as a risk factor (6). An important educational goal of World Thrombosis Day is to arm patients and their families with information to be their own advocates for VTE prevention in high risk settings, such as hospitalisation.

**Underuse of methods of proven efficacy for VTE prevention**

Despite the availability of effective methods for thromboprophylaxis, such as anticoagulant drugs or mechanical devices (7–11), global audits have shown underuse in hospitalised patients at risk. In the ENDORSE study (12), conducted in 358 hospitals across 32 countries, only 58.5% and 30.5% of at risk surgical and medical patients, respectively, received the appropriate thromboprophylaxis recommended by evidence-based guidelines (12). In hospitalised medical patients, appropriate thromboprophylaxis was used in 70% or more of patients in only one country and was used in less than 50% of patients in 23 countries. For surgical patients, the recommended thromboprophylaxis was used in less than 50% of patients in 13 countries, between 51% and 75% in 13 countries, and in over 75% of patients in six countries (12). Therefore, there is systemic underuse of appropriate thromboprophylaxis.

Why is thromboprophylaxis underused? Although there are multiple contributing factors, key among these is the concern about the risk of bleeding with anticoagulant prophylaxis. Clinicians are reluctant to apply the results from clinical trials that were conducted in carefully selected patients to their patients in whom the risk of bleeding is perceived to be higher or the risk of VTE is considered to be lower than that reported in the trials. With this as the argument against universal thromboprophylaxis, extensive research has focused on the development of risk assessment models to identify hospitalised patients whose risk of VTE is sufficiently high to offset the risk of bleeding with anticoagulant thromboprophylaxis. Several such models have been developed (13–16), and some have undergone extensive independent validation (16–21). There also is evidence that elevated plasma levels of D-dimer, a marker of fibrin degradation, may be useful for identifying medically ill patients at increased risk for VTE (22). Current evidence-based guidelines for VTE prevention now recommend the use of risk assessment to personalise the approach to thromboprophylaxis (8, 9).

Experience from the National Health Service in England supports the concept that routine VTE risk assessment in hospitalised patients reduces death and morbidity from VTE.
Systematic VTE risk assessment: Experience from the United Kingdom

In 2010, the Department of Health in England introduced a national target for hospitals within the National Health Service (NHS) with the goal of increasing the number of patients assessed for their risk of VTE (23). The program imposed financial penalties for hospitals that failed to perform VTE risk assessment using a standardised risk assessment tool in at least 90% of patients. The data from evaluations of this initiative have recently become available.

In an observational cohort study that included all patients admitted to NHS hospitals in England between July 2010 and March 2012 (24), Lester et al. tracked VTE-related mortality within 90 days of hospital discharge, and related this mortality to the level of VTE risk assessment at admission. There was a statistically significant reduction in deaths due to VTE in hospitals that reached the targeted level of VTE risk assessment of 90% or more compared with that in hospitals that fell short of this target (relative risk, 0.85; 95% confidence interval, 0.75 to 0.96) (24). The difference was observed in both surgical and non-surgical patients.

Additional data support the value of VTE risk assessment at the time of hospital admission. In a retrospective population-based study (25), Catterick and Hunt determined the rates of VTE mortality and VTE-related readmission at 30 and 90 days in 2011 and 2012 and compared these rates with those expected based on linear regression analysis of the trends observed from 2006–2007 to 2011–2012. The annual national rates of VTE-related mortality for 2011 and 2012 were 91% and 92%, respectively, of the estimated rates and these rates were also lower than the rates observed between 2007 and 2010 (25). In addition, readmission rates related to VTE at 30 and 90 days were 4% lower than the estimated rates in both 2011 and 2012. Although this study has limitations, such a prompt effect on VTE-related death and readmission observed in the first and second year after implementation of routine VTE risk assessment suggests that this strategy reduces fatal and non-fatal hospital-associated VTE. The authors estimated that more than 900 VTE-related deaths were avoided in England during 2011 and 2012 by this strategy (25). Similar data on the reduction of hospital-associated VTE by implementing routine risk assessment are emerging from other countries (26).

Call to action: VTE risk assessment for all hospitalised patients

We urge clinical leaders, hospitals and payers to work together to make VTE risk assessment a priority. The evidence is building that the use of VTE risk assessment saves lives and reduces the burden of VTE. We believe that hospitals and hospital systems should incorporate routine risk assessment for all hospitalised patients. The impact of such a policy should continue to be evaluated through best practices of outcomes research and continuous quality improvement. Government and private insurers should include VTE risk assessment as part of their payment programs to hospitals. This should include demonstration projects for evaluating different payment models and determining the cost-effectiveness of alternate strategies for VTE risk assessment and prevention.

Although the current evidence is not perfect, and no doubt will be updated, the perfect must not be the enemy of the good. We believe that the current evidence is sufficient to take steps now and that by using currently available risk assessment tools, we can reduce death and disability from VTE.

Based on the available evidence, it would be reasonable to use the NHS England risk assessment tool, or alternately, the Caprini risk assessment model for non-orthopaedic surgical patients (13, 14, 20) and the IMPROVE model for hospitalised medical patients (15, 16, 18, 19). VTE risk assessment is not indicated in individual patients undergoing major orthopaedic surgery, such as hip or knee replacement or surgery for hip fracture, because all such patients should receive thromboprophylaxis unless contraindicated. Recent data indicate that measurement of D-dimer is useful as a marker of VTE risk in hospitalised medical patients (22). In the APEX trial (27), medical patients with a D-dimer level more than two times the upper limit of normal appeared to derive the greatest benefit from extended thromboprophylaxis (27). The ongoing MARINER trial is using the IMPROVE risk assessment model together with the D-dimer level to identify

Members of the ISTH Steering Committee for World Thrombosis Day

G.E. Raskob (Chair); P. Angchaisuksiri; A.N. Blanco; H. Buller; H. Daligou; B.J. Hunt; E.M. Hylek; A. Kakkar; S.V. Kontantinides; M. McCumber; C. McIntock; T. Urano; A. Wendelboe; J. J. Weitz

1 College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; 2Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 3División Hemostasia, IHHEMA, Academia Nacional de Medicina, Buenos Aires, Argentina; 4Academic Medical Center, Department of Vascular Medicine, Amsterdam, the Netherlands; 5Uganda Cancer Institute, Kampala, Uganda; 6Thrombosis & Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, UK; 7Boston University School of Medicine, Boston, Massachusetts, USA; 8Thrombosis Research Institute at University College, London, UK; 9Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany; 10Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece; 11National Women’s Health, Auckland City Hospital, Auckland, New Zealand; 12Department of Medical Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan; 13McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
patients who are randomised to a 45-day course of rivaroxaban or placebo after hospital discharge (28). The combined results of the APEX and MARINER trials will better define which medical patients benefit from extended thromboprophylaxis. Now is the time to assess the risk of VTE in all hospitalised patients and to use this information to guide the provision of appropriate thromboprophylaxis. Such an approach will likely save lives and reduce morbidity from non-fatal VTE, and has the potential to reduce the incremental costs of VTE to healthcare systems (29).

Conflicts of interest
Disclosures are on file with the corresponding author.

References